Financial

News

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.

News

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.

News

MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.

News

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

News

Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.